Edgewise Therapeutics, Inc.
EWTX
$44.17
$0.992.29%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.40M | 11.46M | 12.39M | 9.38M | 9.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.94M | 54.12M | 55.98M | 46.86M | 42.61M |
| Operating Income | -61.94M | -54.12M | -55.98M | -46.86M | -42.61M |
| Income Before Tax | -57.33M | -49.01M | -50.22M | -40.67M | -36.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.33M | -49.01M | -50.22M | -40.67M | -36.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.33M | -49.01M | -50.22M | -40.67M | -36.12M |
| EBIT | -61.94M | -54.12M | -55.98M | -46.86M | -42.61M |
| EBITDA | -61.40M | -53.58M | -55.45M | -46.34M | -42.09M |
| EPS Basic | -0.53 | -0.46 | -0.47 | -0.39 | -0.34 |
| Normalized Basic EPS | -0.33 | -0.29 | -0.30 | -0.24 | -0.22 |
| EPS Diluted | -0.53 | -0.46 | -0.47 | -0.39 | -0.34 |
| Normalized Diluted EPS | -0.33 | -0.29 | -0.30 | -0.24 | -0.22 |
| Average Basic Shares Outstanding | 107.67M | 107.12M | 106.01M | 105.49M | 104.94M |
| Average Diluted Shares Outstanding | 107.67M | 107.12M | 106.01M | 105.49M | 104.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |